Seroba Life Sciences — 2017 Investments
3 investments dated 2017 · listed companies and verified rows first · show all
Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells.
BiotechHealthtech
Co-investorsFACIT (Fight Against Cancer Innovation Trust)HealthCapLumira VenturesVenture OntarioYsios CapitalAdams Street Partners+2 more
Prexton Therapeutics was a biopharmaceutical company developing novel therapies for Parkinson's disease, including its lead mGluR4 modulator candidate foliglurax.
BiotechHealthtechMedical DevicesCopenhagen, DK
Co-investorsCardinal PartnersM VenturesSunstone CapitalYsios Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
INNOVO by Atlantic Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.